Brentuximab vedotin desensitization in a patient with refractory Hodgkin's lymphoma-Reference-Cited by-同舟云学术

Brentuximab vedotin desensitization in a patient with refractory Hodgkin's lymphoma

Published:2015-05-06 Issue:4 Volume:95 Page:361-364
ISSN:0902-4441
Container-title:European Journal of Haematology
language:en
Short-container-title:Eur J Haematol

Author:

Arora Anubha¹,Bhatt Vijaya Raj²,Liewer Susanne³,Armitage James O.²,Bociek R. Gregory²

Affiliation:

1. Department of Obstetrics and Gynecology; King George's Medical College; Lucknow India

2. Division of Hematology-Oncology; Department of Internal Medicine; University of Nebraska Medical Center; Omaha NE USA

3. Blood and Marrow Transplant Unit; Department of Pharmacy; Nebraska Medicine; College of Pharmacy; University of Nebraska Medical Center; Omaha NE USA

Publisher

Wiley

Subject

Hematology,General Medicine

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/ejh.12570/fullpdf

Reference13 articles.

1. Results of a pivotal phase II study of brentuximab vedotin for patients with relapsed or refractory Hodgkin's lymphoma;Younes;J Clin Oncol,2012

2. FDG-PET adapted sequential therapy with brentuximab vedotin and augmented ICE followed by autologous stem cell transplant for relapsed and refractory Hodgkin lymphoma;Moskowitz;Blood,2013

3. Brentuximab vedotin in combination with bendamustine for patients with Hodgkin lymphoma who are relapsed or refractory after frontline therapy;LaCasce;Blood,2014

4. The aethera trial: results of a randomized, double-blind, placebo-controlled phase 3 study of brentuximab vedotin in the treatment of patients at risk of progression following autologous stem cell transplant for Hodgkin lymphoma;Moskowitz;Blood,2014

5. A pilot phase II study with brentuximab vedotin followed by ABVD in patients with previously untreated Hodgkin lymphoma: A preliminary report.

Cited by 18 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Immune-inflammatory modulation by natural products derived from edible and medicinal herbs used in Chinese classical prescriptions;Phytomedicine;2024-07

2. Targeting CD 30 in Lymphoid Neoplasms;Precision Cancer Therapies vol 2 ‐ Immunologic Approaches for the Treatment of Lymphoid Malignancies ‐ From Concept to Practice;2024-02-21

3. Hodgkin's Lymphoma;Reference Module in Biomedical Sciences;2023

4. Desensitization to Brentuximab Vedotin after anaphylaxis in refractory Hodgkin's lymphoma;Journal of Oncology Pharmacy Practice;2022-01-21

5. Evaluation of Montelukast for the Prevention of Infusion-related Reactions With Daratumumab;Clinical Lymphoma Myeloma and Leukemia;2020-10